CAB therapy, which involves concurrent use of a gonadotropin-releasing hormone (GnRH) agonist and non-steroidal antiandrogen (CAB-agonist), is more effective than androgen deprivation therapy (ADT) alone and is recommended as the standard treatment for high-risk Pca in Japan. The gene discussed is GNRH1; the disease is posterior cortical atrophy.